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ABSTRACT
Objective: The objective of this study was to examine the pattern of lepra reactions and medicines used in the treatment of lepra reactions in a tertiary 
hospital.
Methods: In this retrospective study, prescriptions of patients treated for the lepra reactions were reviewed to find out the prevalence of Type 1 and 
Type 2 reactions and medicines used in the treatment of lepra reactions.
Results: A total of 66 patients (male 59.1%; female 40.9%) with mean age of 36.6±13.1 years were included in the study. Multibacillary leprosy was 
present in 93.7% patients. A total of 39 (60%) patients had Type 2 reaction whereas 26 (40%) had Type 1 reaction. Mean number of medicines per 
patients was 7.5. Prednisolone was used in 62 (93.9%) patients with mean duration of 33.32±33.2 days, whereas chloroquine was used in 52 (78.8%) 
patients for 36.6±27.9 days. Thalidomide was used in 25 (37.9%) patients. Analgesic and anti-inflammatory and anti-acidity drugs were used 
in 63 (95.4%) patients each whereas paracetamol was given to 41 (62.1%) patients. Antihistamine, antimicrobial agent, and vitamins were given to 
27 (40.9%), 27 (40.9%), and 35 (53.0%) patients, respectively.
Conclusion: Lepra 2 reaction is more common than lepra 1 reaction. Prednisolone and chloroquine are the two most commonly used medicines in the 
treatment of lepra reaction. Similarly, thalidomide, older drug has emerged as common treatment for lepra reaction.
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INTRODUCTION
Leprosy is a chronic disease caused by Mycobacterium leprae, acid-fast 
bacilli and usually presents with skin and nerve lesions [1,2]. Even 
today leprosy is an important public health problem. It can result in 
disfiguring complications in hand, feet, and face including blindness [3]. 
Early diagnosis, availability of effective drugs and strategies for the 
prevention of deformities has tremendously helped to effectively 
manage leprosy and to reduce the incidence of disease [1,4]. However, 
lepra reaction remains a common problem in patients receiving anti-
leprosy therapy. Such reactions can be seen before or after completion 
of therapy [5]. In a study incidence of lepra reactions was 22.8% in 
multibacillary patients during multidrug therapy [6]. Two types of lepra 
reactions (Type 1 and Type 2) are known [7]. Type 1 lepra reactions, 
i.e., delayed hypersensitivity reactions seen in both paucibacillary and 
multibacillary cases can cause permanent damage to the peripheral 
nerves. Type 2 lepra reactions also known as erythema nodosum 
leprosum are acute inflammatory reactions seen only in multibacillary 
leprosy (usually in lepromatous leprosy or sometimes in borderline 
lepromatous leprosy). These reactions are result of immune complex 
response to M. leprae antigenic determinants [8,9]. Lepra reactions pose 
a significant burden in leprosy patients, hence their early identification 
and treatment is important to prevent further complications in the form 
of nerve damage and permanent disabilities [5,10]. There is limited 
data on the prevalence and management pattern of lepra reactions in 
real life setting in Indian patients.
Objective
The objective of this study was to find out the pattern of lepra reactions 
and medicines used in the treatment of lepra reactions in a tertiary 
hospital.
METHODS
In this retrospective study, we included patients treated for the 
management of lepra reactions. Prescriptions of the discharged 
patients were reviewed to examine the prevalence of Type 1 and Type 2 
reactions. The mean and total number of medicines used in the patients 
with lepra reactions was recorded. The study was approved by the 
Institutional Ethics Committee.
Statistical analysis
Continuous data are presented as mean and standard deviation, 
whereas categorical data are presented as number and percentages.
RESULTS
In this study, we reviewed data of 66 patients of which 59.1% were male 
and 40.9% were females. The mean age of patients was 36.6±13.1 years 
(Table 1).
Out of 63 patients in whom type of leprosy was mentioned, 59 (93.7%) 
had multibacillary leprosy whereas 4 (6.3%) had paucibacillary leprosy 
(Fig. 1). In three patients, the classification was not mentioned.
A total of 26 (40%) patients had Type 1 reaction while 39 (60%) patients 
had Type 2 reaction (Fig. 2). Data of one patient were missing. Of the 
39 cases of Type 2 reactions, 11 (28.2%) were steroid-dependent cases 
and 6 (15.4%) were recurrent erythema nodosum leprosum (ENL).
A total number of medicines prescribed to study patients were 493. 
The mean number of medicines per patients was 7.5. Drugs used for 
the treatment of lepra reaction and leprosy are given in Table 2. Table 3 
shows adjuvant drugs used in the treatment of lepra reaction.
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Prednisolone was used in 62 (93.9%) patients with mean duration 
of 33.32±33.2 days whereas chloroquine was used in 52 (78.8%) 
patients for mean period of 36.6±27.9 days. Thalidomide, clofazimine, 
and colchicine were used in 25 (37.9%), 3 (4.5%), and 1 (1.5%) patients, 
respectively (Table 2). The mean duration of use for these three drugs 
was 75.7±41.0, 24.3±8.1 and 30 days, respectively. Clofazimine was 
also used in combination with rifampicin and dapsone in 17 (25.8%) 
patients, whereas combination of rifampicin plus clofazimine was used 
in 2 patients. This was as a part of multidrug regimen for the treatment 
of leprosy. Analgesic and anti-inflammatory and anti-acidity drugs were 
used in 63 (95.4%) patients each. Paracetamol was given to 41 (62.1%) 
patients.
Antihistamine, antimicrobial agent, and vitamins were given to 
27 (40.9%), 27 (40.9%), and 35 (53.0%) patients, respectively (Table 3).
DISCUSSION
Lepra reactions represent a significant burden in patients with leprosy. 
Systematic data from India on the management of lepra reactions in 
real life settings are limited. In this study, we examined the prevalence 
and management pattern of lepra reactions in patients with leprosy. 
Most of the patients with lepra reactions had multibacillary leprosy 
in our study. We observed less common occurrence of Type 1 lepra 
reactions compared to Type 2 reactions. Neuritis, an important cause 
of deformities in leprosy can be managed in hospitals or outpatient 
settings, later being more beneficial in terms of cost reduction [11]. 
Mild cases of Type 1 reaction are treated with analgesics and if there 
is nerve involvement, addition of corticosteroid is required [8]. 
Systemic corticosteroids are the important drugs for the treatment of 
Type 1 reaction [12]. Presentation of Type 2 reactions can be varied 
ranging from mild disease to severe systematic disease [13] and 
are difficult to manage [14]. Type 2 reactions are also treated with 
analgesics and corticosteroids [8]. Thus, overall, the use of analgesics 
and corticosteroids is common in the management of lepra reactions. 
We observed similar pattern of drug usage in our study. Prednisolone 
and analgesic-anti-inflammatory agents were used in 94% and 95.5% 
patients respectively. In addition, paracetamol was used in 41 patients. 
The exact dose and duration of steroid therapy in the treatment of 
lepra reactions is not known. is not known [12]. The mean duration of 
prednisolone use in our study was 33.32 days.
To avoid steroid-related adverse events, steroid sparing agent is 
required for the management of Type 2 lepra reactions [14]. One of such 
agents is chloroquine. Apart from malaria, chloroquine can also be used 
in the management of several other diseases such as extraintestinal 
amoebiasis, rheumatoid arthritis, and lepra reactions [15]. In our 
study, chloroquine was the second most commonly used drug after 
prednisolone. Anti-inflammatory action is the major reason for the use 
of chloroquine in the management of erythema nodosum leprosum. 
The other reasons of chloroquine include wide availability, economic 
advantage, and effectiveness in mild cases of borderline and erythema 
nodosum leprosum reactions [16]. Our study was performed in a 
tertiary care government hospital. Free availability of the medicine in 
hospital pharmacy could be one of the reasons for its common use in 
our study. In severe cases of type reactions or in patients unresponsive 
to corticosteroids, agents like clofazimine or thalidomide may be 
useful [7]. We could not record the severity of reaction, but based on 
the observations of high use of thalidomide, it can be extrapolated 
that prevalence of severe reactions was high. Thalidomide, initially 
used in the management of morning sickness in pregnant women was 
shown to be associated with severe teratogenic effects in children 
when consumed by mothers. Later this drug was reintroduced for the 
treatment of ENL [17]. Thalidomide reduces levels of circulating TNF-α 
Fig. 1: Type of leprosy (Pauci/multibacillary) (N=63)
Fig. 2: Prevalence of lepra reactions (N=65)
Table 1: Baseline demographics
Baseline parameter Result
Total number of patients 66
Mean age (±SD) years (range) 36.6 (±13.1) (Range 9-68 years)
Male, N (%) 39 (59.1)
Female, N (%) 27 (40.9)
SD: Standard deviation
Table 2: Drugs used in the management of lepra reactions and 
leprosy






Rifampicin plus clofazimine 2 (3)
Rifampicin, clofazimine plus dapsone 17 (25.8)
Analgesic and anti-inflammatory 63 (95.5)
Paracetamol 41 (62.1)
Table 3: Adjuvant therapies used in the management of lepra 
reaction







Iron plus folic acid 1 (1.5)
Vitamin plus mineral 30 (45.5)
Others 12 (18.2)
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in patients with ENL [18] and represents a promising agent for the 
treatment of ENL; however, it is not recommended for use in pregnancy.
Cofazimine has been shown to be effective in the dose of 100 mg 
3 times daily for 12 weeks [14]. The benefits of clofazimine include 
anti-inflammatory and steroid sparing effect [19]. The effective is 
usually seen after 4 weeks [8]. Clofazimine is used in both, i.e., treatment 
of leprosy, mainly lepromatous leprosy as well as treatment of lepra 
reactions, i.e., erythema nodosum leprisum [17,20].
In our study, duration of clofazimine was 24.3 days, mainly in the 
treatment of leprosy and rarely in the treatment of lepra reaction.
Pentoxifylline is another effective agent for the treatment of Type 2 
reactions. Pentoxifylline is effective in reducing initial severity, 
whereas clofazimine has comparatively slower onset of action [14]. In 
our study, pentoxifylline was not used. The use of colchicine has also 
been reported in the management of in the management of erythema 
nodosum leprosum due to its anti-inflammatory and immunoregulatory 
action [16]. In our study, the use of colchicines was very low. It was 
used only in one patient in this study. Overall, steroid, analgesic-
anti-inflammatory drugs, paracetamol, chloroquine, thalidomide, 
and clofazimine were the major drugs used in the treatment of lepra 
reactions. In addition to these major medicines, use of adjuvant therapies 
including anti-acidity medicines, antihistamines, antimicrobial therapy 
and vitamins and minerals was common mostly for preventing adverse 
events and improving general health of the patients.
Our study has some limitations. Cross-sectional, retrospective analysis 
of data from single center limits the generalization of findings to whole 
population. The safety of medicines in the treatment of lepra reactions 
and outcomes of the patients are not evaluated. Considering these 
findings, the observations should be carefully extrapolated.
CONCLUSION
Lepra 2 reaction is more common than lepra 1 reaction. Prednisolone 
and chloroquine are the two most commonly used medicines in the 
treatment of lepra reaction whereas colchicine use is uncommon. 
Thalidomide, older drug is commonly used for the treatment of lepra 
reaction in government tertiary hospital set up.
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